SCHEMBL4773076

SCHEMBL4773076

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(C#N)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PER2 O15055 1/20 0.43
CRY1 Q16526 1/20 0.43
CRY2 Q49AN0 1/20 0.43
GAA P10253 1/20 0.40
NR3C1 P04150 3/20 0.40
ALDH1A1 P00352 2/20 0.39
RECQL P46063 1/20 0.39
PGR P06401 2/20 0.38
POLB P06746 2/20 0.37
LMNA P02545 2/20 0.37
MAPT P10636 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HCRTR2 O43614 1/20 0.35
MMP2 P08253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773417 0.96 PER2 (0.41) PER2CRY1CRY2GAANR3C1
SCHEMBL4771201 0.85 LMNA (0.50) CRY1CRY2GAAALDH1A1RECQL
SCHEMBL4777553 0.84 ALDH1A1 (0.49) PER2CRY1CRY2GAAALDH1A1
SCHEMBL4773540 0.82 GAA (0.43) GAAALDH1A1RECQLPOLBLMNA
SCHEMBL4772377 0.82 PNMT (0.47) GAAALDH1A1RECQLPOLBLMNA
SCHEMBL4777644 0.81 GAA (0.45) GAAALDH1A1RECQLPOLBLMNA
SCHEMBL4777413 0.81 KDM4E (0.52) PER2CRY1CRY2GAANR3C1
SCHEMBL4767920 0.80 NR1H4 (0.50) GAAALDH1A1LMNAMAPTMEN1
SCHEMBL4773541 0.80 GAA (0.42) GAAALDH1A1RECQLLMNAMAPT
SCHEMBL4792816 0.79 ALDH1A1 (0.41) GAAALDH1A1RECQLPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 PER2 3931/4885CRY1 4457/4885CRY2 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.